MTOR and pancreatic neuroendocrine tumor: The RADIANT-3 trial, for instance, showed an improved progression-free survival (PFS) of 11 months for patients suffering from advanced, progressive pancreatic NETs (pNETs) treated with the mTOR inhibitor everolimus compared to 4.6 months for placebo [2].